Cargando…
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
BACKGROUND: Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B...
Autores principales: | Walter, Maggie C, Reilich, Peter, Thiele, Simone, Schessl, Joachim, Schreiber, Herbert, Reiners, Karlheinz, Kress, Wolfram, Müller-Reible, Clemens, Vorgerd, Matthias, Urban, Peter, Schrank, Bertold, Deschauer, Marcus, Schlotter-Weigel, Beate, Kohnen, Ralf, Lochmüller, Hanns |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617000/ https://www.ncbi.nlm.nih.gov/pubmed/23406536 http://dx.doi.org/10.1186/1750-1172-8-26 |
Ejemplares similares
-
Deflazacort-induced Acneiform Eruptions
por: Bashir, Mohammed Shakeel Mohammed, et al.
Publicado: (2017) -
The Clinical Outcome Study for dysferlinopathy: An international multicenter study
por: Harris, Elizabeth, et al.
Publicado: (2016) -
Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects
por: Petersen, Jens A., et al.
Publicado: (2015) -
De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany
por: König, Kirsten, et al.
Publicado: (2019) -
Oculopharyngeal muscular dystrophy as a rare cause of dysphagia
por: Werling, Sarah, et al.
Publicado: (2015)